Qiagen N.V. (NYSE:QGEN) Receives Consensus Rating of “Hold” from Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have been given a consensus recommendation of “Hold” by the twelve research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $44.9789.

QGEN has been the subject of a number of analyst reports. Barclays set a $38.00 price objective on shares of Qiagen and gave the company an “equal weight” rating in a report on Wednesday, April 29th. Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Citigroup restated a “hold” rating on shares of Qiagen in a report on Monday, May 18th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $43.00 price objective on shares of Qiagen in a report on Thursday, April 30th. Finally, TD Cowen restated a “hold” rating and set a $40.00 price objective (down from $46.00) on shares of Qiagen in a report on Thursday, May 7th.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen announced new research-use-only digital PCR assays to support Bundibugyo ebolavirus research and surveillance, highlighting continued product innovation and demand for its QIAcuity platform. QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
• Positive Sentiment: One analysis said Qiagen’s margins, cash flow and debt-free balance sheet could help stabilize the investment case despite the weaker outlook, suggesting the company still has financial flexibility. Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
• Neutral Sentiment: Another recent note outlined Qiagen’s 2026 growth drivers, including new launches, automation via Connect, and QIAstat-Dx menu expansion, but also acknowledged choppy demand conditions. QIAGEN Business Breakdown and Growth Drivers for 2026
• Neutral Sentiment: Zacks Research trimmed several future EPS estimates for Qiagen, but maintained a Hold rating, signaling caution rather than a major change in sentiment. Qiagen N.V. research updates
• Negative Sentiment: Qiagen cut its 2026 growth outlook after missing Q1 expectations, which is the main reason investors are selling the stock today. Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Qiagen, adding legal overhang and potentially increasing uncertainty for shareholders. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. – QGEN

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Groupama Asset Managment acquired a new position in Qiagen during the first quarter valued at approximately $500,000. Groupe la Francaise grew its holdings in Qiagen by 7.1% during the first quarter. Groupe la Francaise now owns 133,161 shares of the company’s stock valued at $5,331,000 after purchasing an additional 8,781 shares during the period. Janus Henderson Group PLC acquired a new position in Qiagen during the first quarter valued at approximately $14,647,000. Amundi grew its holdings in Qiagen by 12.4% during the first quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after purchasing an additional 524,959 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in Qiagen by 46.8% during the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after purchasing an additional 876 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Down 0.1%

Shares of NYSE:QGEN opened at $36.62 on Friday. Qiagen has a one year low of $32.53 and a one year high of $57.81. The company has a 50 day moving average of $37.69 and a 200-day moving average of $44.75. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. The stock has a market cap of $7.55 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 3.64 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The company had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. During the same quarter in the previous year, the company earned $0.56 EPS. On average, sell-side analysts forecast that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s dividend payout ratio is presently 13.61%.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.